Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases

Journal of Medicinal Chemistry

Volumn 46, Issue 18, 2003, Pages 3877-3882

  Woodard, Cassandra L ^a   Li, Zhiyu ^a   Kathcart, April K ^a   Terrell, James ^a   Gerena, Lucia ^a   Lopez Sanchez, Miriam ^a   Kyle, Dennis E ^a   Bhattacharjee, Apurba K ^a   Nichols, Daniel A ^a   Ellis, William ^a   Prigge, Sean T ^a,b   Geyer, Jeanne A ^a   Waters, Norman C ^a,b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 OXO 2 PHENYLETHYLIDENE) 1,3 DIHYDROINDOL 2 ONE; 3 (2 OXOPROPYLIDENE) 1,3 DIHYDROINDOL 2 ONE; 3 (3,3 DIMETHYL 2 OXOBUTYLIDENE) 1,3 DIHYDROINDOL 2 ONE; 3 (4 CHLOROBENZYLIDENE) 1,3 DIHYDROINDOL 2 ONE; 3 [2 (4 BROMOPHENYL) 2 OXOETHYLIDENE] 1,3 DIHYDROINDOL 2 ONE; 5 BROMO 3 (2 OXO 2 PHENYLETHYLIDENE) 1,3 DIHYDROINDOL 2 ONE; ALSTERPAULLONE; BUTYROLACTONE; COMPOUND 52; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; INDIRUBIN 3' OXIME; KENPAULLONE; OLOMOUCINE; OXINDOLE; PROTEIN PFMRK; PROTEIN PFPK5; PURVALANOL A; ROSCOVITINE; STAUROSPORINE; UNCLASSIFIED DRUG; WHIP 180;

AMINO ACID ANALYSIS; ARTICLE; CONTROLLED STUDY; CROSS REACTION; CRYSTAL STRUCTURE; DATA BASE; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIMALARIALS; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HUMANS; INDOLES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0042420753     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0300983     Document Type: Article

References (41)

1. Sausville, E. A.; Zaharevitz, D.; Gussio, R.; Meijer, L.; Louarn-Leost, M.; Kunick, C.; Schultz, R.; Lahusen, T.; Headlee, D.; Stinson, S.; Arbuck, S. G.; Senderowicz, A. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol. Ther. 1999, 82, 285-292.
2. Fischer, P. M.; Lane, D. P. Inhibitors of Cyclin-Dependent Kinases as Anti-Cancer Therapeutics. Curr. Med. Chem. 2000, 7, 1213-1245.
3. Senderowicz, A. M.; Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 2000, 92, 376-387.
4. Xiao, Z.; Waters, N. C.; Woodard, C. L.; Li, Z.; Li, P. K. Design and synthesis of Pfmrk inhibitors as potential antimalarial agents. Bioorg. Med. Chem. Lett. 2001, 11, 2875-2878.
5. Meijer, L.; Leclerc, S.; Leost, M. Properties and potential-applications of chemical inhibitors of cyclin-dependent kinases. Pharmacol. Ther. 1999, 82, 279-284.
6. Waters, N. C.; Geyer, J. A. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development. Expert Opin. Ther. Targets 2003, 7, 7-17.
7. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
8. Arnot, D. E.; Gull, K. The Plasmodium cell-cycle: facts and questions. Ann. Trop. Med. Parasitol 1998, 92, 361-365.
9. Doerig, C.; Chakrabarti, D.; Kappes, B.; Mathews, K. The cell cycle in protozoan parasites. In Progress in Cell Cycle Research; Meijer, L., Jézéquel, A., Ducommun, B., Eds.; Plenum Publishers: New York, 2000; 163-183.
10. Harmse, L.; van Zyl, R.; Gray, N.; Schultz, P.; Leclerc, S.; Meijer, L.; Doerig, C.; Havlik, I. Structure-activity relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum. Biochem. Pharmacol. 2001, 62, 341-348.
11. Li, Z.; Le Roch, K.; Geyer, J. A.; Woodard, C. L.; Prigge, S. T.; Koh, J.; Doerig, C.; Waters, N. C. Influence of human p16(INK4) and p21(CIP1) on the in vitro activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases. Biochem. Biophys. Res. Commun. 2001, 288, 1207-1211.
12. Graeser, R.; Franklin, R. M.; Kappes, B. Mechanisms of activation of the cdc2-related kinase PfPK5 from Plasmodium falciparum. Mol. Biochem. Parasitol. 1996, 79, 125-127.
13. Le Roch, K.; Sestier, C.; Dorin, D.; Waters, N.; Kappes, B.; Chakrabarti, D.; Meijer, L.; Doerig, C. Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue. J. Biol. Chem. 2000, 275, 8952-8958.
14. Doerig, C.; Endicott, J.; Chakrabarti, D. Cyclin-dependent kinase homologues of Plasmodium falciparum. Int. J. Parasitol. 2002, 32, 1575-1585.
15. Ross-Macdonald, P. B.; Graeser, R.; Kappes, B.; Franklin, R.; Williamson, D. H. Isolation and expression of a gene specifying a cdc2-like protein kinase from the human malaria parasite Plasmodium falciparum. Eur. J. Biochem. 1994, 220, 693-701.
16. Graeser, R.; Wernli, B.; Franklin, R. M.; Kappes, B. Plasmodium falciparum protein kinase 5 and the malarial nuclear division cycles. Mol. Biochem. Parasitol. 1996, 82, 37-49.
17. Li, J. L.; Robson, K. J.; Chen, J. L.; Targett, G. A.; Baker, D. A. Pfmrk, a MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization. Eur. J. Biochem. 1996, 241, 805-813.
18. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J.; Detivaud, L.; Leclerc, S.; et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 1994, 224, 771-786.
19. Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio, R.; Sausville, E. A.; Meijer, L.; Kunick, C. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 1999, 42, 2909-2919.
20. Gray, N.; Detivaud, L.; Doerig, C.; Meijer, L. ATP-site directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 1999, 6, 859-875.
21. Schoepfer, J.; Fretz, H.; Chaudhuri, B.; Muller, L.; Seeber, E.; Meijer, L.; Lozach, O.; Vangrevelinghe, E.; Furet, P. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J. Med. Chem. 2002, 45, 1741-1747.
22. Legraverend, M.; Tunnah, P.; Noble, M.; Ducrot, P.; Ludwig, O.; Grierson, D. S.; Leost, M.; Meijer, L.; Endicott, J. Cyclin-Dependent Kinase Inhibition by New C-2 Alkynylated Purine Derivatives and Molecular Structure of a CDK2-Inhibitor Complex. J. Med. Chem. 2000, 43, 1282-1292.
23. Noble, M. E.; Endicott, J. A. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacol. Ther. 1999, 82, 269-278.
24. Hanks, S. K.; Quinn, A. M.; Hunter, T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241, 42-52.
25. Waters, N. C.; Woodard, C. L.; Prigge, S. T. Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum. Mol. Biochem. Parasitol. 2000, 107, 45-55.
26. Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 2000, 43, 1-18.
27. Hardcastle, I. R.; Golding, B. T.; Griffin, R. J. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 325-348.
28. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. 2001, 44, 4339-4358.
29. Kent, L. L.; Hull-Campbell, N. E.; Lau, T.; Wu, J. C.; Thompson, S. A.; Nori, M. Characterization of novel inhibitors of cyclin-dependent kinases. Biochem. Biophys. Res. Commun. 1999, 260, 768-774.
30. Davis, S. T.; Benson, B. G.; Bramson, H. N.; Chapman, D. E.; Dickerson, S. H.; Dold, K. M.; Eberwein, D. J.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Griffin, R. J.; Harris, P. A.; Hassell, A. M.; Holmes, W. D.; Hunter, R. N.; Knick, V. B.; Lackey, K.; Lovejoy, B.; Luzzio, M. J.; Murray, D.; Parker, P.; Rocque, W. J.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001, 291, 134-137.
31. Arris, C. E.; Boyle, F. T.; Calvert, A. H.; Curtin, N. J.; Endicott, J. A.; Garman, E. F.; Gibson, A. E.; Golding, B. T.; Grant, S.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Lawrie, A. M.; Newell, D. R.; Noble, M. E.; Sausville, E. A.; Schultz, R.; Yu, W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 2000, 43, 2797-2804.
32. Barvian, M.; Boschelli, D. H.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey, P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 2000, 43, 4606-4616.
33. Kim, K. S.; Sack, J. S.; Tokarski, J. S.; Qian, L.; Chao, S. T.; Leith, L.; Kelly, Y. F.; Misra, R. N.; Hunt, J. T.; Kimball, S. D.; Humphreys, W. G.; Wautlet, B. S.; Mulheron, J. G.; Webster, K. R. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J. Med. Chem. 2000, 43, 4126-4134.
34. Soni, R.; Muller, L.; Furet, P.; Schoepfer, J.; Stephan, C.; Zumstein-Mecker, S.; Fretz, H.; Chaudhuri, B. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun. 2000, 275, 877-884.
35. Honma, T.; Yoshizumi, T.; Hashimoto, N.; Hayashi, K.; Kawanishi, N.; Fukasawa, K.; Takaki, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S.; Morishima, H. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem. 2001, 44, 4628-4640.
36. Goodsell, D. S.; Olson, A. J. Automated docking of substrates to proteins by simulated annealing. Proteins 1990, 8, 195-202.
37. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
38. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. 2001, 44, 4615-4627.
39. Trager, W.; Jensen, J. B. Human malaria parasites in continuous culture. Science 1976, 193, 673-675.
40. Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 1979, 16, 710-718.
41. Jeffrey, P. D.; Russo, A. A.; Polyak, K.; Gibbs, E.; Hurwitz, J.; Massague, J.; Pavletich, N. P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995, 376, 313-320.